The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 7544840.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We attempt to elucidate the performance of serum prostate specific antigen (PSA) as a screening test for prostate cancer. We analyzed sera stored since 1980 in a nested case-control study. The 36 patients with prostate cancer had a markedly greater mean serum PSA level than did 68 subjects without cancer (22.71 versus 2.67, respectively, p < 0.0001). Among the controls 24% had a serum PSA of greater than 4.0 micrograms/l. A serum PSA value exceeding 4.0 micrograms/l. in 1980 was associated with a 20-fold excess risk of cancer between 1981 and 1986, and an 8-fold risk between 1987 and 1991. Diagnosis of clinically significant prostate cancer can be advanced substantially by serum PSA testing. However, the large number of high serum PSA values in men who remained free of clinical disease emphasizes the need for a more specific screening test.
Medical subject headings
- Prostate-Specific Antigen
- Prostatic Neoplasms